Bangladesh
· Delayed Price · Currency is BDT Central Pharmaceuticals Statistics
Total Valuation
Central Pharmaceuticals has a market cap or net worth of BDT 1.07 billion. The enterprise value is 1.35 billion.
| Market Cap | 1.07B |
| Enterprise Value | 1.35B |
Important Dates
The last earnings date was Thursday, October 31, 2024.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Central Pharmaceuticals has 119.80 million shares outstanding. The number of shares has increased by 2.36% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 119.80M |
| Shares Change (YoY) | +2.36% |
| Shares Change (QoQ) | -2.51% |
| Owned by Insiders (%) | 25.89% |
| Owned by Institutions (%) | n/a |
| Float | 88.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.76 |
| PB Ratio | 1.25 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -22.84 |
| EV / Sales | 12.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.34.
| Current Ratio | 1.18 |
| Quick Ratio | 0.34 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.49 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 1.51M |
| Profits Per Employee | -799,609 |
| Employee Count | 74 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.01% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -31.01% |
| 50-Day Moving Average | 11.29 |
| 200-Day Moving Average | 19.64 |
| Relative Strength Index (RSI) | 39.70 |
| Average Volume (20 Days) | 1,076,955 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Central Pharmaceuticals had revenue of BDT 111.75 million and -59.17 million in losses. Loss per share was -0.48.
| Revenue | 111.75M |
| Gross Profit | -15.15M |
| Operating Income | -45.14M |
| Pretax Income | -63.26M |
| Net Income | -59.17M |
| EBITDA | -20.65M |
| EBIT | -45.14M |
| Loss Per Share | -0.48 |
Balance Sheet
The company has 1.18 million in cash and 286.60 million in debt, giving a net cash position of -285.42 million or -2.38 per share.
| Cash & Cash Equivalents | 1.18M |
| Total Debt | 286.60M |
| Net Cash | -285.42M |
| Net Cash Per Share | -2.38 |
| Equity (Book Value) | 850.24M |
| Book Value Per Share | 7.10 |
| Working Capital | 67.15M |
Cash Flow
| Operating Cash Flow | -126,003 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -13.56%, with operating and profit margins of -40.40% and -52.95%.
| Gross Margin | -13.56% |
| Operating Margin | -40.40% |
| Pretax Margin | -56.61% |
| Profit Margin | -52.95% |
| EBITDA Margin | -18.48% |
| EBIT Margin | -40.40% |
| FCF Margin | n/a |
Dividends & Yields
Central Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.36% |
| Shareholder Yield | -2.36% |
| Earnings Yield | -5.42% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on November 26, 2018. It was a forward split with a ratio of 1.05.
| Last Split Date | Nov 26, 2018 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
Central Pharmaceuticals has an Altman Z-Score of 0.77. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.77 |
| Piotroski F-Score | n/a |